ATreg/Actileucel (ATX-002)
Prevention of Graft-versus-Host Disease (GvHD)
Phase 1/2Active
Key Facts
About ActiTrexx
ActiTrexx is a clinical-stage biotech pioneering an allogeneic, activated regulatory T cell (Treg) therapy platform to re-balance the immune system. Its lead candidate, ATreg/Actileucel (ATX-002), is in a Phase Ib/II trial for preventing graft-versus-host disease (GvHD) and represents a 'one product fits all' approach without tissue matching. Founded and led by experts in immunology and cell therapy, the company is supported by German public research grants and focuses on developing potentially curative treatments for severe autoimmune and inflammatory conditions.
View full company profile